IRVINE, Calif., May 7, 2012 /PRNewswire/ -- Aviir Diagnostic Laboratory has entered into a contractual agreement for ancillary diagnostics laboratory testing as a participating provider with TRPN and its 10 million lives network.
Three Rivers Provider Network (TRPN) was founded in 1996 as a company that was contracted to provide services for several major clients. At that time, its clients needed to access a network that would grant PPO type discounts without incurring balance billing risks for their members. Over time, given superior results and the high levels of satisfaction of service that were achieved, TRPN was prompted by other companies that focused on group health and workers compensation to perform similar type services for them.
Since that time, TRPN has evolved into the largest and fastest growing proprietary PPO network in the United States. The TRPN network is now comprised of more than 600,000 total providers, including more than 5,000 hospitals and 70,000 ancillary facilities. Through its clients, approximately 10 million lives now have access to the TRPN PPO network.
Aviir was founded in 2005 by cardiologists and scientists from the Stanford University School of Medicine to focus on discovery, development and commercialization of innovative diagnostic tests. The biotechnology company specializes in developing proprietary diagnostic tests that will assist in identifying patients who are truly at high risk for the development of a cardiac event. Aviir's proprietary MiRisk™ and TruRisk™ assessments objectively identify, by a simple blood draw, individuals who are at a high risk of a cardiac event over the next five years. Aviir's CLIA laboratory (Irvine, CA) complements these novel tests with a wide range of additional tests for risk assessment and therapeutic monitoring of cardiovascular disease and related metabolic disorders – including pharmacogenomics and genetic tests. www.aviir.com
"There is currently a significant yet unmet clinical need in the medical community for more effective ways to identify individuals at high risk of a heart attack who are missed by current evaluation methods. Providing an accurate assessment of the patient's overall heart health is the first step in prevention of cardiovascular disease," stated Douglas Harrington, M.D., Chief Executive Officer of Aviir.
"At Aviir, our ultimate goal is to help physicians identify those patients who are at serious risk of experiencing a heart attack but are completely unaware of their precarious condition. Armed with better information, physicians will be able to customize individualized treatment plans with the goal of improving patient therapeutic compliance, reducing their risk of heart attacks, and decreasing the overall cost of care," Dr. Harrington added.
For more information:
Marketing, Communications Manager
|SOURCE Aviir Diagnostic Laboratory|
Copyright©2010 PR Newswire.
All rights reserved